Erythrocyte membrane stabilization by indomethacin
Indian Journal of Pharmacology 1993; 25: 173
LETTER TO THE EDITOR ERYTHROCYTE MEMBRANE STABILIZATION BY INDOMETHACIN
(Accepted for publication: April 06, 1993)
The erythrocyte osmotic fragility tests has been used
Figure 1. Osmotic fragility profile of erythrocytes. Each point is
as a measure of red cell tensile strength and is
the mean of at least four experiments.
related to cellular deformability which is a significantaspect of red cell function.’ Indomethacin, a non-
steroidal anti-inflammatory drug, was found to in-duce slight membrane changes in erythrocytes.²We studied the effect of indomethacin on erythrocyte
osmotic fragility to ascertain its membrane stabilizing effect.
Young albino rats (Charles foster) weighing 200-
2509 were maintained on commercial rat diet (Lip-
ton Co., India) and water, They were divided intotwo groups. Animals in group I served as control
and group II were administered indomethacin 0.4166mg/kg, p.o., bd x 5 days. After 5 days of drug treat-
ment blood was collected in heparin (10 IU/ml) from
the caudal vein. The osmotic fragility determinations
were done by the method of Dacie and Lewis.³ The
NaCl concentration of 50% hemolysis was taken
as a measure of mean erythrocyte fragility (MEF).
membranes and organelles, any effect of a drug on
In control rats, the osmotic fragility (O.F.) profile is
the osmotic hemolysis can be interpreted as an
almost a sigmoidal curve whereas in indomethacin
effect on the cell membrane. The stabilizing effect
treated animals the O.F. profile is shifted to the left
of indomethacin on erythrocyte membrane may be
which is due to decreased osmotic fragility showing
membrane stabilization (Figure 1). The MEF is sig-
shown to cause phospholipids disruption, an impor-
nificantly (P < 0.01) decreased in indomethacin
tant component of red cell membranes and as-
treated rats. The MEF of control and indomethacin
sociated structural changes in the red cell membrane
treated rats are 0.740 ± 0.008 and 0.711 ± 0.002%
lndomethacin is one of the most potent inhibitorsof the prostaglandin forming cyclooxygenase which
IMTIAZ AHMAD* AND MOHAMMAD SUHAI L
reduces the production and tissue concentration of
to act on erythrocytes in such a way that it causes
* Present Address: Institute of Social Health Welfare Rural
been reported that ingestion of indomethacin in-
Development and Educational Society, ISWRDES (India),
duces slight membrane changes in erythrocytes.²
Since erythrocytes are free from intracellular
U.S. Department of the Army TM8-227-4. Laboratory proce-
dures in clinical hematology. Washington D.C., U.S. Govt.
4. Goodman LS, Gilman A. The pharmacological basis of
therapeutics. 7th eds. New York: McMillan Publishing Co.
Mazorow DL, Hang A, Bull R, McGroarty EJ. Effect of aspirin,
indomethacin and sodium salicylate on human erythrocytemembranes as detected with electron spin resonance
5. Taniguchi M, Alkawa M, Sakagami T Effect of prostaglandin
spectroscopy. Throm Res 1985;40:779-92.
and polyphloretin phosphate on hemolysis of human
eryrhrocytes. J Biochem 1982;91:1173-9.
Dacie JV, Lewis S.M. Practical hematology. Orient
Original paper 257 K.P. Walker, U. Amon Institute Interdisciplinary Therapy Centre PsoriSol GmbH, Specialist Hospital for Dermatology and Allergology, Hersbruck Bibliography time sleep and skin appearance. Approx. 88% DOI 10.1055/s-2008-1077493 of patients with atopic dermatitis rated the This study investigated the additive effects of wearing comfort as pleasant or ex
AARP MedicareRx Preferred (PDP) plan STEP THERAPY ALGORITHMS Treatment Group Description Step 1 : Metformin Step 2 : Actoplus Met Step 1 : Metformin Step 2 : Actos Step 1 : One of the following: Step 2 : Amitiza Step 1 : One of the following Tier 1 or Tier 2 antidepressants: a. SSRI b. SNRI c. Bupropion d. Mirtazepine Step 2 : Emsam Step 1 : Fome